Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ramucirumab
Related studies linked through entity extraction aliases.
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE3
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
- Status
- UNKNOWN
- Phase
- PHASE1
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers
- Status
- UNKNOWN
- Phase
- PHASE3
A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1